Serotonin (5-HT) exerts pleiotropic effects in the human cardiovascular system. Some of the effects are thought to be mediated via 5-HT4 receptors, which are expressed in the human atrium and in ventricular tissue. However, a true animal model to study these receptors in more detail has been hitherto lacking. Therefore, we generated, for the first time, a transgenic (TG) mouse with cardiac myocyte-specific expression of the human 5-HT4 receptor. RT-PCR and immunohistochemistry revealed expression of the receptor at the mRNA and protein levels. Stimulation of isolated cardiac preparations by isoproterenol increased phospholamban phosphorylation at Ser 16 and Thr 17 sites. 5-HT increased phosphorylation only in TG mice but not in wild-type (WT) mice. Furthermore, 5-HT increased contractility in isolated perfused hearts from TG mice but not WT mice. These effects of 5-HT could be blocked by the 5-HT 4 receptor-selective antagonist GR-125487. An intravenous infusion of 5-HT increased left ventricular contractility in TG mice but not in WT mice. Similarly, the increase in contractility by 5-HT in isolated cardiomyocytes from TG mice was accompanied by and probably mediated through an increase in L-type Ca 2ϩ channel current and in Ca 2ϩ transients. In intact animals, echocardiography revealed an inotropic and chronotropic effect of subcutaneously injected 5-HT in TG mice but not in WT mice. In isolated hearts from TG mice, spontaneous polymorphic atrial arrhythmias were noted. These findings demonstrate the functional expression of 5-HT4 receptors in the heart of TG mice, and a potential proarrhythmic effect in the atrium. Therefore, 5-HT4 receptorexpressing mice might be a useful model to mimic the human heart, where 5-HT 4 receptors are present and functional in the atrium and ventricle of the healthy and failing heart, and to investigate the influence of 5-HT in the development of cardiac arrhythmias and heart failure. serotonin; arrhythmia; transgenic mice; signal transduction MOST OF THE SEROTONIN (5-HT) in the blood originates from enterochromaffine cells of the gastrointestinal tract (53). 5-HT is released by these cells and is avidly taken up by platelets. Platelets seem to be the main source of 5-HT that influences the cardiovascular system. These influences include vasoconstriction, an increase in platelet aggregation, apoptosis of cardiac cells, augmentation in beating rate, the generation of arrhythmias (27), valvular heart disease (49), and positive inotropic and relaxant effects (for an overview, see Ref. 29).
At present, seven groups of 5-HT-receptors have been distinguished (5-HT 1 -5-HT 7 ) (29) . The 5-HT 4 receptor mediates the positive inotropic effect in humans (8, 31, 33, 51) . In the human atrium and ventricle, mRNAs of several splice variants of the 5-HT 4 receptor have been found (6, 2, 9) .
In isolated multicellular preparations from human atria, 5-HT exerts a positive inotropic effect and a relaxant (or lusitropic) effect (31, 33) . These effects were accompanied by increases in cAMP content and elevated PKA activity (32) . In addition, in cardiomyocytes from human atria, 5-HT augmented current through L-type Ca 2ϩ channels due to higher channel availability (24) , phospholamban (PLB) phosphorylation (19) , and enlarged cellular contractility (51) . Activation of PKA is necessary for the 5-HT-mediated increase of L-type Ca 2ϩ current in atrial cardiac myocytes (43) . These effects were reversed by 5-HT 4 receptor-selective antagonists and, therefore, are regarded as 5-HT 4 receptor mediated. In isolated preparations from the human ventricle, only in preparations from some patients was a positive inotropic effect of 5-HT noted (8) . The reason for this remains unclear. In the presence of phosphodiesterase inhibitors, consistently positive inotropic effects in human ventricular preparations were observed (8) .
Intravenous injection of 5-HT exerts a positive chronotropic effect in humans (22) . This effect may be 5-HT 4 receptor mediated because the increase of pacemaker current (a current implied to mediate positive chronotropic effects in the sinus node) by 5-HT in isolated cardiomyocytes from the human atrium is sensitive to the appropriate receptor blockers (46) .
Moreover, 5-HT can induce atrial arrhythmias in isolated trabeculae from the human atrial myocardium (31) . 5-HT may, e.g., thus initiate and/or sustain atrial fibrillation (AF) (27) . In isolated human atrial cardiomyocytes, 5-HT prolonged action potentials and initiated late depolarizations (44) . In the mouse heart, 5-HT 4 receptors seem to be expressed only during embryogenesis and disappear after birth (26) . A cell culture model with adenoviral expression of human 5-HT 4 receptors in adult rat cardiac myocytes was established to explore receptor signaling in cardiomyocytes. This study (12) demonstrated coupling of transfected 5-HT 4 receptors to the cAMP pathway. So far, there have been no studies of the 5-HT 4 receptor in intact mice.
The present work was initiated to gain further insight into the cardiac effects of 5-HT. To this end, we generated, for the first time, a mouse with cardiac myocyte-directed expression of the human 5-HT 4 receptor. We hypothesized that in this model system, it would be possible to dissect in detail the physiological function of this receptor in the heart. Specifically, we wanted to know whether the overexpression of 5-HT 4 receptors could lead to positive inotropic or chronotropic effects in the heart and/or arrhythmias. (NIH Pub. No. 85-23, Revised 1996) . Animals were handled and maintained according to protocols approved by the Animal Welfare Committee of the University of Halle (approval no. 42502-02-691 MLK). Total RNA was extracted from the human heart using TRIzol reagent (Invitrogen) according to the manufacturer's protocol. A 1,206-bp fragment encompassing 12 bp of the 5=-untranslated region, the entire 5-HT 4a receptor-coding region, and 10 bp of the 3=-untranslated region was generated using RT-PCR methodology. The sequence was confirmed by sequencing. The RT-PCR product was ligated into a mouse cardiac ␣-myosin heavy chain promoter expression cassette containing the simian virus 40 (SV40) transcriptional terminator, similar to methods previously described (18) . The transgene, which was composed of the ␣-myosin heavy chain promoter, the entire protein-coding region for the human 5-HT 4a receptor, and the SV40 polyadenylation signal sequence, was isolated from the parent plasmid as a 7.1-kbp NruI fragment and used for the microinjection of fertilized mouse eggs (FVB/N). Transgenepositive mice were identified by Southern blot analysis and PCR assay of tail genomic DNA and thereafter crossed to the CD1 background.
MATERIALS AND METHODS

Isolation of 5-HT4a receptor cDNA and generation of transgenic mice. This investigation conformed with the National Institutes of Health Guide for the Care and Use of Laboratory Animals
RT-PCR analysis. Total RNA from mouse hearts was isolated as described above. Reverse transcription was performed with 4 g RNA using random primers (Transcriptor High-Fidelity cDNA Synthesis Kit, Roche Applied Science, Mannheim, Germany), and PCR amplification was performed using Ampliqon Taq DNA polymerase (Biomol, Hamburg, Germany) according to the manufacturer's instructions. As a control, each sample was also analyzed without reverse transcription. As a positive control, a plasmid containing human 5-HT 4a cDNA was used as a template. The following primer pair was used for the 5-HT4a receptor: forward 5=-ACATCTCTGGACGTCCTGCT-3= and reverse 5=-CCGACTGAGGCCTGCTCTCG-3= (product size: 439 bp).
Western blot analysis. Ventricular homogenates were prepared in 300 l of 10 mM NaHCO 3 and 100 l of 20% SDS. Mixtures were kept at 25°C for 30 min before centrifugation to remove debris. Thereafter, supernatants (called homogenates) were kept at Ϫ20°C until further analysis. Western blot analysis was performed as previously reported (18) . Aliquots of 100 g protein were loaded per lane. Bands were detected using enhanced chemifluorescence (GE Healthcare, Munich, Germany) and a Storm PhosphorImager (GE Healthcare). The following primary antibodies were used: polyclonal rabbit anti 5-HT 4 receptor (Chemicon, Millipore), polyclonal rabbit anti calsequestrin (CSQ), monoclonal mouse anti-sarco(endo)plasmic reticulum Ca 2ϩ -ATPase (SERCA)2a, polyclonal rabbit anti-triadin (TRD), and polyclonal rabbit anti-junctin (JCN) (all kindly provided by L. R. Jones, Indianapolis, IN) as well as monoclonal mouse anti-PLB (A-1, Badrilla, Leeds, UK), polyclonal rabbit anti-phospho-PLB (antibodies were raised against PLB peptide phosphorylated at Ser 16 or at Thr 17 , Badrilla). Characteristics and use of these antibodies have been reported repeatedly by our group (e.g., Ref. 34) .
Histological analyses. To analyze the morphological features of the transgenic (TG) myocardium, dewaxed and rehydrated tissue sections of formaldehyde-fixed ventricular samples were stained with hematoxylin and eosin (18) .
Immunohistochemical techniques. For immunohistochemical analysis, sections of paraffin-embedded hearts were immunoreacted with antibodies to the 5-HT 4 receptor in the same way as previously described (10, 18) . Nuclei were counterstained with 4=,6-diamidino-2-phenylindole (Sigma). The controls were as follows: 1) omission of incubation with primary antibody, 2) substitution of primary antibody with rabbit IgG at the same final concentration, and 3) incubation in media containing primary antibody that had been preincubated with a 10-fold molar excess of the corresponding control peptide. Control incubations resulted in a lack of immunostaining. Images shown are representative of at least five independent experiments, which gave similar results.
Echocardiography. Echocardiography in spontaneously breathing mice was performed under anesthesia with 1.5% isofluorane as previously described using a 10MHz Toshiba ultrasound probe (14) . Twodimensional images and M-mode tracings were recorded from the parasternal short-axis view at the midpapillary level. Fractional shortening of the heart was calculated from the M-mode left ventricular (LV) diameters as follows: (LVEDD Ϫ LVESD)/LVEDD, where LVEDD is the LVend-diastolic diameter and LVESD is LV end-systolic diameter.
Hemodynamic performance. LV catheterization was performed in closed-chest mice anesthetized with tribromoethanol (15 l/g body wt of a 2.5% solution) as previously described (18) . Through the right carotid artery, a 1.8-Fr size polyethylene catheter (Micromed, Houston, TX) was inserted into the LV. Analog pressure signals were obtained using a pressure transducer (UM-310, Micromed), recorded, and digitized at a sampling rate of 1,000 Hz with the PowerLab system (ADInstruments, Spechbach, Germany). The left jugular vein was cannulated for intravenous access, and increasing doses of 5-HT were administered. Heart rate, blood pressure, and first derivatives of LV pressure (ϩdP/dt and ϪdP/dt) were measured continuously.
Isolation of cardiomyocytes. Ventricular myocytes were isolated from control and TG mouse hearts using a previously published protocol (34) . In brief, hearts were perfused for 5 min at 2 ml/min with a Ca 2ϩ -free solution (solution A) composed of (in mM) 140 NaCl, 5.8 KCI, 0.5 KH2PO4, 0.4 Na-H2PO4, 0.9 MgSO4, 10 HEPES, and 11.1 glucose (pH 7.1) followed by a perfusion for 30 min with solution A supplemented with 0.2 mg/ml collagenase (type D, Roche Molecular Biochemicals). The Ca 2ϩ concentration was gradually increased during digestion. After enzymatic digestion, hearts were perfused for 10 min with solution A, and ventricles were cut into several pieces before myocytes were separated by filtration through a nylon mesh.
Ca 2ϩ transients and whole cell L-type Ca 2ϩ currents. Measurement of Ca 2ϩ transients were performed as previously described (18) . Cells were incubated with the fluorescence dye Indo-1 and stimulated at 1 Hz. Excitation was at 365 nm, and the emitted fluorescence was recorded at 405 and 495 nm. The ratio of fluorescence at the two wavelengths was used as an index of cytosolic Ca 2ϩ . L-type Ca 2ϩ currents and cell capacitance were recorded as previously described (34) .
Cell contraction experiments. Myocytes were superfused with HEPES buffer and voltage clamped to a holding potential of Ϫ80 mV (50) . Trains of 50-ms voltage steps to 0 mV were continuously applied at 1 Hz. Sarcomere length was continuously recorded using the IonOptix MyoCam system. In the case of pharmacological interventions, contractions were additionally analyzed 2 min after drug application (average of 10 contractions).
Work-performing heart preparations. Work-performing heart preparations were used as previously described (34) . Mice were anesthetized intraperitoneally with 2.0 g/kg body wt urethane and treated with 1.5 units of heparin. Hearts were removed from the opened chest, immediately attached by the aorta to a 20-gauge cannula, and perfused retrogradely with oxygenized Krebs-Henseleit buffer (37.4°C) containing (in mM) 118 NaCl, 25 NaHCO3, 0.5 Na-EDTA, 4.7 KCl, 1.2 KH2PO4, 1.2 MgSO4, 2.5 CaCl2, and 11 glucose. The venous return (preload) and aortic pressure (afterload) were adjusted to 5 ml/min cardiac output and 50 mmHg, respectively. Heart rate, aortic pressure, LV pressure (systolic, diastolic, and end diastolic), and atrial pressure were measured and monitored continuously. ϩdP/dt and ϪdP/dt were calculated with a computer program (PowerLab, ADInstruments).
HPLC detection of 5-HT and catecholamines. Epinephrine and norepinephrine levels in plasma and whole heart tissue as well as 5-HT levels in whole heart tissue were estimated by HPLC with fluorometric detection (13) . Hearts were perfused with buffer in the Langendorff mode for 20 min to wash the coronaries free of blood. After perfusion, the heart was freeze clamped at the temperature of liquid nitrogen and kept frozen until further analysis. Briefly, 100 mg of frozen heart tissue were homogenized in 1 ml of 0.4 M HClO 4 containing 0.1% ascorbic acid, 0.1% cysteine, 3 mM glutathione, and 2 mM EDTA at 0°C. After centrifugation (5 min, 6,000 g, 0°C), 20 l of the supernatant were neutralized with 3 l of 2.5 M NaOH and directly injected into the HPLC column. HPLC separation was performed on a eurosphere 100 -5C8 column (250 ϫ 4.4 mm inner diameter, Knauer) at 30°C. 5-HT was eluted isocratically at a flow rate of 0.6 ml/min using a mobile phase consisting of methanol (200 ml) and 0.1 M KH 2PO4 buffer (600 ml) adjusted to pH 4.5 (containing 170 mg 1-octanesulfonic acid and 60 mg EDTA per liter). Fluorescence detection was carried out at 345 nm with excitation at 285 nm.
Langendorff-perfused hearts. The heart was excised under anesthesia and retrogradely perfused on a vertical Langendorff apparatus, and monophasic action potentials were recorded from the right atrial epicardium and LV epicardium as previously described (16, 35) . After an initial stabilization period, the intrinsic ventricular rhythm was observed after atrioventricular nodal block for 10 min to detect bradycardia-dependent arrhythmias. Thereafter, fix-frequent and programmed right atrial and ventricular stimulation was performed via an octapolar murine electrophysiology catheter. Action potential durations and arrhythmias were digitally analyzed using previously published computer-assisted techniques (21) .
Data analysis. Data shown are means Ϯ SE. Statistical significance was estimated by ANOVA followed by Bonferroni's t-test or using a 2 -test as appropriate. P values of Ͻ0.05 were considered significant. Drugs and materials. 1-{2-[(methyl-sulphonyl) amino]ethyl}-4-piperdinyl-methyl-5-fluoro-2-methoxy-1H-indole-3-carboxylate (GR-125487) and 5-HT hydrochloride were obtained from Sigma. All other chemicals were of analytic grade. Deionized water was used throughout the experiments. Stock solutions were freshly prepared daily.
RESULTS
The human 5-HT 4a receptor was expressed under control of the ␣-myosin heavy chain promoter in cardiomyocytes of TG mice. With RT-PCR, a signal for the human 5-HT 4a receptor only was detected in mRNA isolated from the TG heart but not in mRNA from the wild-type (WT) heart (Fig. 1A ). This indicates transcriptional activity of the transgene. In the same cDNA samples, no RT-PCR product for the mouse 5-HT 4 receptor was found (data not shown). 5-HT 4 receptor expression did not lead to cardiac hypertrophy over the time studied (Table 1) , and the lifespan of TG mice was not different from WT mice. Expression of the transgene at the protein level was confirmed by immunohistochemistry ( Fig. 1 , B and C). The RT-PCR analysis of total RNA isolated from the hearts of wild-type (WT) and TG mice revealed the expression of human 5-HT4a receptor mRNA only in TG mice. Controls were omission of reverse transcription (RTϪ) and a plasmid as the template for PCR containing human 5-HT4a receptor cDNA (Ctr). B: detection of 5-HT4 receptors (green) in heart sections via immunohistology. Note the sarcolemmal localization of the signal corresponding to the receptor and its overexpression in sections from TG mice. C: higher magnification demonstrating the striated pattern of expression consistent with localization of the 5-HT4a receptor with the t-tubule system. green signal specific for the 5-HT 4 receptor showed a striated pattern of expression, consistent with localization of the 5-HT 4 receptor within the t-tubule system (Fig. 1C) . In addition, the signal was prominent in the disci intercalares, consistent with sarcolemmal expression of the transgene. Control incubations, as stated in MATERIALS AND METHODS, resulted in a lack of immunostaining. We did not detect any fibrosis in animals using appropriate staining or other microscopic changes in morphology (data not shown). Next, we studied if overexpression of the 5-HT 4 receptor altered the expression of important Ca 2ϩ -regulatory proteins in TG mice: protein expressions of PLB, SERCA, CSQ, TRD, and JCN remained unchanged (Fig. 2) . The ratios (TG/WT) of the mean expression levels were as follows: SERCA, 1.13; CSQ, 1.05; TRD, 1.03; JCN, 0.90; and PLB, 0.94 (n ϭ 3-6). The phosphorylation state of PLB at Ser 16 was enhanced by isoproterenol in cardiomyocytes from both TG and WT mice (Fig. 3A) . However, 5-HT enhanced PLB phosphorylation only in cardiomyocytes from TG mice and not from WT mice (Fig. 3A) . This effect was blocked by the 5-HT 4 antagonist GR-125487 (Fig. 3B) . In a similar way, in isolated work-performing hearts, isoproterenol increased the phosphorylation of PLB at Ser 16 (and Thr 17 ) in TG and WT mice. However, 5-HT enhanced the phosphorylation of PLB at Ser 16 (and Thr 17 ) only in perfused hearts from TG mice but not from WT mice (Fig. 4A) . Moreover, the higher basal Thr 17 phosphorylation of PLB in TG mice was remarkable (Fig. 4B) . In the presence of the 5-HT 4 receptor-selective antagonist GR-125487 (1 M), 5-HT-induced (1 M) phosphorylation of PLB at Ser 16 or Thr 17 amounted to 109 Ϯ 13% or 105 Ϯ 11%, respectively (n ϭ 3 each), of the control value (no drug addition) in perfused hearts from TG mice. Hence, the effects of exogenously added 5-HT (1 M) on dual PLB phosphorylation can tentatively be regarded as being 5-HT 4 receptor mediated. Moreover, with GR-125487 (1 M) alone, phosphorylation of PLB at Ser 16 or Thr 17 amounted to 108 Ϯ 13% or 107 Ϯ 12%, respectively (n ϭ 3), in perfused hearts from TG mice. The latter data are shown in original autoradiogramms in Fig. 4B , namely, that the enhanced basal phosphorylation state of Thr 17 on PLB in TG mice can be reduced to control values by perfusion with a 5-HT 4 receptor antagonist. This indicates that the enhanced basal PLB Thr 17 phosphorylation in perfused hearts is 5-HT 4 receptor mediated, presumably due to endogenous 5-HT acting via this receptor (Fig. 4B) .
Recently, the ability of neonatal rat cardiac myocytes to synthesize 5-HT has been reported (23) . Therefore, one can ask whether overexpression of a 5-HT 4 receptor changes the concentrations of 5-HT in heart tissue or plasma. As blood contains high levels of 5-HT, experiments were performed in isolated spontaneously beating hearts, where blood was washed out by retrograde perfusion with saline buffer. In tissue samples from 
Values are means Ϯ SE; n ϭ 8 -10 mice. Body weights and heart weights from wild-type (WT) and transgenic (TG) mice were measured. Moreover, values of the catecholamines norepinephrine, epinephrine, and serotonin (5-HT) were determined in plasma and, as a comparison, in samples from isolated buffer-perfused hearts. *P Ͻ 0.05, TG vs. WT mice. these hearts, a substantial amount of 5-HT was still detectable (Table 1) . 5-HT levels were unchanged in TG hearts compared with WT hearts (Table 1) . As a comparison, levels of catecholamines were measured in plasma and the heart. Whereas levels of epinephrine were similar in plasma from WT and TG mice, levels of norepinephrine were higher in plasma from TG mice than from WT mice.
In ventricular cardiomyocytes from TG mice, exogenous 5-HT stimulated L-type Ca 2ϩ current, but not in WT mice ( Fig. 5 and Table 2 ). However, ␤-adrenergic signaling was not impaired, because isoproterenol augmented this current in both WT and TG mice (Fig. 5 and Table 2 ). Moreover, 5-HT increased Ca 2ϩ transients only in cardiomyocytes from TG mice but not from WT mice (Fig. 5E) . Namely, 1 M 5-HT increased the amplitude of Ca 2ϩ transients in cardiomyocytes from TG mice by 106.2 Ϯ 21.1% (P Ͻ 0.05), whereas 5-HT was devoid of any effect on cardiomyocytes from WT mice. These data fit well with the contractile findings. In isolated electrically driven cardiomyocytes from TG mice, 5-HT increased contractility, but not in cardiomyocytes from WT mice ( Table 2) . Additionally, LV pressure in cannulated mice was elevated by the infusion of 5-HT in TG mice but not in WT mice. For instance, 5-HT increased ϪdP/dt by 28.7 Ϯ 8.07% (P Ͻ 0.05) of the predrug value (n ϭ 10) in the LV of TG mice, whereas in WT mice 5-HT at the same dose was inactive (97.2 Ϯ 5.92% of the predrug value). Likewise, echocardiographic parameters of contractility (fractional shortening) were increased by 5-HT in intact TG mice but not in WT mice (Table 3 ). This stimulatory effect of isoproterenol was comparable in WT and TG mice (Table 3) . Finally, the same findings could be repeated in isolated work-performing hearts devoid of humoral and neural control of cardiac function (Table 4) . In these preparations, the inotropic effect was manifest as an increase in ϩdP/dt and the relaxant effect by the raise in ϪdP/dt. The positive inotropic and relaxant effects of 5-HT in TG mice were completely blocked after the application of the antagonist GR-125487 (Table 4) . Interestingly, in isolated hearts, the basal beating rate was increased in TG mice compared with WT mice, and this increase was not influenced by GR-125487 (Table 4) . However, this phenomenon was only noted in vitro (working heart preparations). In vivo (echocardiography), the basal heart rate was not different between TG and WT mice (Table 3) . Therefore, and because of the resistance to GR-125487, it is unlikely that this tachycardia was directly 5-HT 4 receptor mediated. Thus, we can only speculate that the mechanism leading to tachycardia in vitro is compensated by neural or humoral regulation of the heart beat in vivo. As a control, some animals were pretreated with reserpine (5 mg/kg, 16 h before the experiment) (42) . The ability of reserpine under these conditions to greatly deplete cardiac stores of catecholamines and 5-HT is shown in a representative HPLC experiment in Fig. 6 . In isolated perfused hearts from reserpine-pretreated TG animals, the effects of 5-HT on the force of contraction were still present (with 1 M 5-HT, the force of contraction amounted to 87.2 Ϯ 11.8% of nonreserpine-treated TG hearts, n ϭ 5, P Ͼ 0.05), indicating that efficacy of 5-HT was comparable. This argues against an indirect positive inotropic effect of 5-HT in hearts from TG animals via the release of catecholamines. This conclusion is consistent with our contractile effects of 5-HT in cardiomyocytes, which do not contain nerve cells or nerve endings as a source of catecholamines.
In addition, a higher propensity toward arrhythmias was noted in TG mice compared with WT mice (Fig. 7) . Arrhythmias were not noted in any of the hearts from WT mice. The pressure tracings of TG hearts showed an absolute arrhythmia at the LV level (Fig. 7A ). For instance, as shown in the top trace of Fig. 7A , one beat is missing, and, later, a larger beat is noted, consistent with postrest potentiation. As shown in the bottom trace of Fig. 7A , an additional contraction with lower size follows a normal beat. This may be a mechanical equivalent to a delayed afterdepolarization. In this set of experiments, none of the 13 WT hearts exhibited ventricular arrhythmias, whereas arrhythmias under basal conditions (before the addition of exogenous 5-HT), as shown in Fig. 7A , were seen in 7 of 13 TG hearts (P Ͻ 0.05). These arrhythmias were observed in LV pressure recordings. We also inspected the pressure recordings in the left atrium of these mice (Fig. 7A ) and failed to detect arrhythmias. Regrettably, our setup did not allow us to measure pressure in the right atrium. Hence, we hypothesize at present that these arrhythmias (Fig. 7A) are of LV origin, but we cannot exclude arrhythmogenesis, at least in part, from the right atrium in TG animals. An additional preliminary set of experiments with perfusion of hearts from reserpine-treated TG mice (n ϭ 5) resulted in one heart with basal ventricular arrhythmias (absence of exogenous 5-HT) and one heart with arrhythmias after exogenous 5-HT. Reserpine pretreatment of mice did not affect the basal beating rate (107 Ϯ 11% of untreated hearts, n ϭ 5, P Ͼ 0.05). In six (of six) isolated spontaneously beating right atrial preparations that exhibited arrhythmias (that is, in the absence of exogenous 5-HT), 1 M GR-125487 was able to block all arrhythmias within, at most, 20 min. Three examples are shown in Fig. 8 . Under control conditions (no addition of GR-125487), arrhyth- Fig. 4 . PLB phosphorylation in isolated perfused working heart preparations from WT (A) and TG mice (A and B) (age: 12-14 wk). Perfused hearts were treated before being frozen with Iso, 5-HT, or GR at the concentrations indicated. Thereafter, cardiac extracts were performed and subjected to SDS-PAGE and Western blot analysis. Those blots were then probed with antibodies specific for CSQ (as a loading control), PLB-PS16, or PLB phosphorylated at Thr 17 (PLB-PT17).
mias in six (from six) preparations persisted (P Ͻ 0.05). This argues that the arrhythmias in TG cardiac preparations under basal conditions are due to stimulation of the overexpressed 5-HT 4 receptor by endogenous 5-HT. In isolated Langendorffperfused hearts, atrial monophasic action potentials were recorded. Here, spontaneous atrial arrhythmias were observed in four of eight TG mouse hearts but in only one of eight WT mouse hearts (P Ͻ 0.05) (Fig. 7B , in the absence of exogenous 5-HT). After the application of exogenous 5-HT to the hearts without spontaneous arrhythmias, two additional hearts developed arrhythmias, but in WT hearts no effect of 5-HT was detectable. This was consistent with our observations in isolated cells: in ventricular cardiomyocytes from TG mice but not from WT mice, Ca 2ϩ transients exhibited spontaneous oscillating increases in cytosolic Ca 2ϩ content after stimulation with 1 M 5-HT (P Ͻ 0.05, n ϭ 6; Fig. 7C ). Interestingly, in only one of six TG cells, spontaneous Ca 2ϩ oscillations were observed after ␤-adrenergic stimulation with 1 M isoproterenol. We speculate here that the spontaneous arrhythmias may be mediated via Ca 2ϩ -calmodulin-dependent protein kinase. This speculation is supported by the finding that in hearts from TG mice the phosphorylation of PLB at Thr 17 under basal conditions was higher than in hearts from WT mice (P Ͻ 0.05; Fig. 4) . Additionally, in the first preliminary experiments, an inhibitor of Ca 2ϩ -calmodulin-dependent protein kinase (W7) suppressed spontaneous ventricular arrhythmias in five (of five) preparations from TG mice (P Ͻ 0.05).
DISCUSSION
Aspects of the model generated. We chose to express the human 5-HT 4a receptor in mice because 1) the 5-HT 4a receptor was the first to be cloned; 2) its pharmacological profile is well studied, e.g., in heterologous expression systems; and 3) it is one of two main isoforms of the 5-HT 4 receptor in the human heart (7), which might confer to this model additional clinical relevance. Based on the functional experiments reported here, we did not detect any functional expression of 5-HT 4 receptors in WT mice, whereas overexpression of the human 5-HT 4 receptor was functionally noticeable in TG mice. This conclusion is supported by our immunohistological experiments, even if it seems that in WT hearts low amounts of 5-HT 4 receptors are expressed. Nevertheless, we cannot rule out that in WT samples some unspecific binding of the antibody occurred. On the other hand, 5-HT 4 mRNA has been detected in the mouse atrium (39) .
Signal transduction. The signal transduction pathway of the human 5-HT 4 receptor in the heart of TG mice is, in all respects studied in the present report, equal to that of the human heart: its stimulation by 5-HT is accompanied by increased current through L-type Ca 2ϩ channels in TG hearts, presumably via the activation of PKA. This increased current [probably via Ca 2ϩ -induced Ca 2ϩ release from the sarcoplasmic reticulum (for a review, see Ref. -calmodulin-dependent protein kinase. The dual phosphorylation of PLB (at Ser 16 and Thr 17 ) is thought to explain, at least in greater part, the inotropic and relaxant effects of ␤-adrenergic stimulation (for a review, see Ref. 40 ) and, by analogy, would account for the similar mechanical responses to exogenous 5-HT in hearts from TG mice. The fact that the 5-HT 4 receptor-selective antagonist GR-125487 attenuated the 5-HT-induced phosphorylation of PLB at Ser 16 or Thr 17 is consistent with 5-HT 4 receptor-mediated PLB phosphorylation. This phosphorylation pattern is similar to our findings in human atrial preparations (19) . The fact that basal Thr 17 phosphorylation (in the absence of exogenous 5-HT) was increased in perfused hearts from TG mice and was reduced by GR-125487 to WT levels is indicative that spontaneous arrhythmias (see below) in this model may be due in part to the basal activation of Ca 2ϩ -calmodulindependent protein kinase in hearts from TG mice. It can be asked why we did not notice tachycardia under in vivo conditions (echocardiography; Table 3 ) but in isolated perfused hearts (Table 4 ). One would assume that endogenous 5-HT should stimulated pacemaker cells in the sinoatrial node in both experimental setups. At present, we can only speculate that under in vivo conditions (echocardiography; Table 3 ), humoral and neural pathways are active on pacemaker cells and antagonize a (presumed) action of 5-HT on these cells. Specifically, an increase of vagal activity would have such an inhibitory and compensatory effect.
Comparison with ␤ 1 -adrenoceptor-overexpressing mice. In contrast with ␤ 1 -adrenoceptor-overexpressing mice [which show fibrosis (15)], no histological alterations were noted in our TG mice. It is noteworthy that ␤ 1 -adrenoceptor overexpression presumably uses, at least in part, the same signal Values are means Ϯ SE; n ϭ 13 hearts. The following contractile parameters were measured using the work-performing mode: LV pressure, the maximum rate of LV pressure development (ϩdP/dt), and the maximum rate of LV pressure decline (ϪdP/dt). Hearts were left untreated (Ctr) or received Iso, 5-HT, GR-125487, or GR-125487 ϩ 5-HT, as described in MATERIALS AND METHODS. *P Ͻ 0.05, TG vs. WT mice; †P Ͻ 0.05 vs. Ctr. transduction system as the 5-HT 4 receptor, namely, adenylyl cyclase. In contrast, ␤ 1 -adrenoceptor-overexpressing mice exhibit fibrosis, hypertrophy, and, ultimately, heart failure and a reduced lifespan (15) . However, in ␤ 2 -adrenoceptor-overexpressing mice, no fibrosis was discernable (41) . The different phenotypes of ␤ 1 -adrenoceptor versus. ␤ 2 -adrenoceptor overexpression are not completely understood but can be tentatively explained by the fact that the ␤ 2 -adrenoceptor couples in part to other pathways than the ␤ 1 -adrenoceptor, for instance, to inhibitory G proteins. The same may be true for the 5-HT 4 receptor. For instance, 5-HT 4 receptors can couple via G␤␥ to L-type Ca 2ϩ channels and, in addition, to ion channels (11, 45) , and they can activate G13 (47) . However, one can argue that 5-HT 4a receptor-mediated increases (in contrast to 5-HT 4b receptor-mediated increases) in cAMP production (in transfected HEK-293 cells) were not PTX sensitive, and, therefore, these receptors were regarded as not to signal via PTXsensitive G proteins (45) . It remains to be shown whether the effects of 5-HT in this mouse model are still present after treatment of TG mice with PTX (which would be the prediction).
Further uses of 5-HT 4 TG mouse models. It is of interest to note that in WT mice at the concentrations (up to 100 M) tested, 5-HT did not affect any functional parameters tested in this study. For instance, 5-HT did not increase the force of contraction (or the beating rate) in hearts from WT mice. Hence, mice provide an excellent background to test structureeffect relationships of the 5-HT 4 receptor in vivo. For instance, one could test mutations (25) in the heart of receptor-overexpressing mice. In future studies, heart failure could be induced in our or related TG mice (e.g., via aortic banding) to scrutinize how this intervention affects 5-HT 4 receptor function: for instance, in rats with congestive heart failure, 5-HT 4 receptors have been found in the LV, but functional responsiveness to 5-HT was mediated through both 5-HT 2A and 5-HT 4 receptors (5). In hearts from normal rats, only atrial (not ventricular) responsiveness to 5-HT was reported, and it was mediated through 5-HT 2A receptors (36) . In human ventricles (from nonfailing and failing hearts), 5-HT can increase the force of contraction via 5-HT 4 receptors (8) . Therefore, TG mice may present an appropriate model system for the study of 5-HT 4 receptors in nonfailing and failing human hearts.
Elevated plasma norepinephrine. It is not readily apparent why norepinephrine values in plasma (but not cardiac tissue; Table 1 ) are higher in TG mice than in WT mice. It is unlikely that the mechanism of neural release or the metabolism of norepinephrine is altered via 5-HT 4 receptor overexpression. The promoter used (the ␣-myosin heavy chain promoter) is only active in myocytes and not in neural cells (52) ; therefore, an altered release mechanism from neurons due to additionally overexpressed 5-HT 4 receptors in the neurons themselves is not compatible with the literature. Thus, we can presently only speculate that norepinephrine elevation in plasma may result from some afferent nerve stimulation leading to a central compensatory (or adjunct) mechanism. However, we failed to detect any cardiac hypertrophy or fibrosis in these mice. The exact reason for the enhanced norepinephrine plasma levels remains to be elucidated.
Arrhythmias. We noted, under basal conditions and after stimulation by the addition of exogenous 5-HT, more arrhythmias in isolated cardiac preparations from TG mice than from WT mice. These arrhythmias included both ventricular and supraventricular arrhythmias. Regarding the underlying postreceptor mechanism, it is tempting to speculate that increases in free intracellular Ca 2ϩ led to afterdepolarizations (4), possibly via Ca 2ϩ -dependent autoactivation of Ca 2ϩ -calmodulin-dependent protein kinase feeding into a vicious circle. The increased basal Thr 17 phosphorylation of PLB noted in TG hearts, which was antagonized by the selective 5-HT 4 receptor antagonist GR-125487, is supportive of this hypothesis. There is a wealth of literature for the involvement of Ca 2ϩ -calmodulin-dependent protein kinase in the genesis of cardiac arrhythmias (for a review, see Ref. 1). However, additional mechanisms, such as the action of 5-HT 4 receptors on pacemaker current in cardiomyocytes, could play an additional role (44, 46) . Reserpine (via extensive reduction of 5-HT levels in the heart) and a selective 5-HT 4 receptor antagonist (GR-125487) could significantly reduce the incidence of arrhythmias in cardiac preparations from TG mice. These findings are consistent with the hypothesis that endogenous 5-HT, acting on overexpressed (functionally active) 5-HT 4 receptors (in TG mice), might underlie the arrhythmias we noted under basal conditions.
Not only does 5-HT lead to arrhythmias in human hearts, but the propensity of 5-HT to induce arrhythmias was even more pronounced in atrial preparations from patients chronically treated with ␤-adrenoceptor blockers (31, 51) . Interestingly, in AF, mRNA expression of 5-HT 4 receptors was found to be altered. However, at present, the results are somewhat inconclusive. While Grammer and coworkers (20) provided evidence for a decrease of 5-HT 4 receptor mRNA in atrial tissue from patients with chronic AF, more recently increased 5-HT 4b receptor mRNA expression in chronic AF has been reported (38) . In the very same study (38) , the authors noted decreased mRNA expression of 5-HT 4b receptors in acute AF. Thus, while the details are controversial, these data support a role for 5-HT via 5-HT 4 receptors in the etiology of human arrhythmias.
Conceivable uses of the present model system and comparison with other models. The present model may be useful to test the safety of (novel) 5-HT 4 receptor (partial) agonists and to ascertain an ability of new 5-HT 4 receptor antagonists to stop arrhythmias. For instance, cisapride, a compound affecting the tonus of the gastrointestinal system and a partial agonist of human atrial 5-HT 4 receptors (32), was found to evoke tachyarrhythmias (3, 28) . Our TG system might be useful for preclinical testing of newer similar compounds. In the past, others (37, 48) have successfully used instrumented pigs to study the antiarrhythmic effects of 5-HT 4 receptor antagonistic drugs. The incidence of 5-HT-induced arrhythmias was greatly enhanced with a concomitant application of phosphodiesterase 3 inhibitors, at least in vitro (8) , and caution should thus be used when combining a phosphodiesterase inhibitory drug with a drug that exerts partial agonistic properties on 5-HT 4 receptors (30) . Moreover, it has been suggested that 5-HT 4 receptor antagonists might be useful to suppress supraventricular and ventricular arrhythmias in patients treated with phosphodiesterase inhibitors. Consistent with this, there is evidence for a protective function of phosphodiesterase 3 against 5-HT-evoked effects in isolated preparations from the human atrium (17) .
The main new findings of the present work are as follows. Here, we report the first mouse model for cardiac overexpres- sion of the 5-HT 4 receptor. We demonstrated that overexpression of 5-HT 4 receptors in the mouse heart led to 5-HTmediated phosphorylation of regulatory proteins, increased Ca 2ϩ channel currents, and increased intracellular Ca 2ϩ transients, which probably explain the positive inotropic effect of 5-HT in these hearts. Furthermore, we noted arrhythmias in these TG mice, probably due to Ca 2ϩ overload of the sarcoplasmic reticulum. This model might be useful to better understand the role of 5-HT 4 receptors in health and disease.
